<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409304</url>
  </required_header>
  <id_info>
    <org_study_id>DTMS-ERB10/18-2011</org_study_id>
    <nct_id>NCT01409304</nct_id>
  </id_info>
  <brief_title>Effectiveness of Deep Transcranial Magnetic Stimulation in Depression</brief_title>
  <official_title>Effectiveness of Deep Transcranial Magnetic Stimulation for Treating Major Depression: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Douglas Mental Health University Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Douglas Mental Health University Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We intend to investigate whether deep transcranial magnetic stimulation (DTMS), a novel brain
      stimulation technique, is effective for treating major depression. We hypothesize that 4
      weeks of DTMS will be associated with significant improvements in depressive and anxious
      symptoms without significant side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this pilot study is to assess, naturalistically, the effectiveness of deep
      transcranial magnetic stimulation (DTMS) in a sample of subjects with treatment-resistant
      depression. To do this, enrolled depressed outpatients will be assigned to receive 4 weeks of
      daily DTMS and will be evaluated at baseline and during week 5. We hypothesize that treatment
      with DTMS will be associated with significant clinical improvements in depressive and anxious
      symptoms, and will be well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>21-item Hamilton Depression Rating Scale (HAM-D21)</measure>
    <time_frame>week 5</time_frame>
    <description>Response to treatment is defined as a ≥ 50% reduction in the scores of the HAM-D21. Remission is defined as a HAM-D21 score ≤ 9.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)</measure>
    <time_frame>week 5</time_frame>
    <description>Response to treatment is defined as a ≥ 50% reduction in the scores of the QIDS-SR. Remission is defined as a QIDS-SR score ≤ 5.</description>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Transcranial Magnetic Stimulation (DTMS)</intervention_name>
    <description>DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a current major depressive disorder (according to the DSM-IV-TR) that has
             not improved after ≥ 1 but ≤ 5 adequate antidepressant trial(s) in the current episode

          -  Baseline score ≥ 15 on the QIDS-C

          -  Stable medication regimen (&gt; 4 weeks)

        Exclusion Criteria:

          -  Psychotic features in the current episode

          -  Lifetime history of psychotic disorders and/or bipolar I or II disorders

          -  Substance or alcohol abuse/dependence in the past 6 months

          -  Lifetime history of a major neurological disease (e.g., Parkinson's, stroke)

          -  Uncontrolled medical disease (e.g., cardiovascular, renal)

          -  Pregnancy and/or lactation

          -  Presence of a specific contraindication for DTMS (e.g., personal history of epilepsy,
             metallic head implant)

          -  Hearing loss

          -  Personal history of abnormal brain MRI findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo T Berlim, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University &amp; Douglas Mental Health University Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuromodulation Research Clinic, Douglas Mental Health University Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4H1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.douglas.qc.ca/page/neuromodulation-program</url>
    <description>Neuromodulation Research Clinic, Douglas Mental Health University Institute</description>
  </link>
  <reference>
    <citation>Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, Lerer B, Zangen A. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. J Affect Disord. 2011 Feb;128(3):235-42. doi: 10.1016/j.jad.2010.06.038. Epub 2010 Jul 21.</citation>
    <PMID>20663568</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Harel EV, Roth Y, Braw Y, Most D, Katz LN, Sheer A, Gersner R, Zangen A. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimul. 2009 Oct;2(4):188-200. doi: 10.1016/j.brs.2009.08.002. Epub 2009 Sep 16.</citation>
    <PMID>20633419</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Roth Y, Harel EV, Braw Y, Sheer A, Zangen A. A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation. Clin Neurophysiol. 2007 Dec;118(12):2730-44. Epub 2007 Oct 30.</citation>
    <PMID>17977787</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Douglas Mental Health University Institute</investigator_affiliation>
    <investigator_full_name>MARCELO T. BERLIM</investigator_full_name>
    <investigator_title>Director, Neuromodulation Research Clinic</investigator_title>
  </responsible_party>
  <keyword>Major depression</keyword>
  <keyword>Deep Transcranial Magnetic Stimulation</keyword>
  <keyword>Naturalistic Trial</keyword>
  <keyword>DTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

